Gynecologic Cancer News

Niraparib demonstrated clinically relevant activity among women with heavily pretreated ovarian cancer, particularly those with homologous recombination deficiency-positive, platinum-sensitive disease, according to findings from the phase 2 QUADRA study published in The Lancet Oncology.

Non-Latino white adolescents and young adults who are cancer survivors have a lower risk for subsequent death compared with survivors of other races and ethnicities, according to research published in JNCI Cancer Spectrum.

Many women with newly diagnosed breast cancer did not receive BRCA testing, despite having insurance coverage and access to specialty genetic services, according to a study published in Journal of the National Cancer Institute.

HPV vaccination programs significantly decrease HPV infections and cervical lesions among girls and women, as well as anogenital wart diagnoses among girls, women, boys and men, according to a systematic review and meta-analysis published in The Lancet.

The ability to harness the human immune system and use it to fight cancer remains a significant area of focused research and is likely to remain so until the next great advancement occurs. Meanwhile, companies like Fate Therapeutics are going all-in on their own versions of immune effector cell therapies to treat cancer.

Incidence rates of aggressive uterine cancer subtypes have increased rapidly since the turn of the century, with racial disparities reflected in higher rates and shorter survival among black women, according to a study published in Journal of Clinical Oncology.

The HER2-targeting antibody-drug conjugate trastuzumab duocarmazine demonstrated clinical activity and appeared safe among patients with heavily pretreated HER2-expressing metastatic cancer, according to results of a dose-escalation and dose-expansion study published in The Lancet Oncology.

The FDA approved bevacizumab-bvzr for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic nonsquamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.

Experts at a congressional briefing today addressed the need for the U.S. to actively pursue the goal of eradicating HPV and its associated cancers.

About one in three cancer survivors, representing nearly 5.4 million people in the United States, reported experiencing chronic pain, with one in six survivors enduring high-impact chronic pain that limits life or work activities, according to a research letter published in JAMA Oncology. “Chronic pain is one of the most common long-term effects of cancer treatment and has been linked with an impaired quality of life, lower adherence to treatment, and higher health care costs,” Changchuan Jiang, MD, MPH, resident in internal medicine at Mount Sinai Hospital, and colleagues wrote. “Nevertheless, there is a paucity of information regarding the prevalence of, and risk factors for, the development of chronic pain among cancer survivors.”